Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462262 | 1.00 | KMT2A (1.00) | KMT2AMEN1GAAUSP2MAPT | |
| SCHEMBL24121622 | 0.85 | MEN1 (0.73) | KMT2AMEN1GAAMAPTHTT | |
| SCHEMBL20777920 | 0.82 | MEN1 (0.70) | KMT2AMEN1GAAGRIN2DGRIN3B | |
| SCHEMBL24121640 | 0.81 | MEN1 (0.68) | KMT2AMEN1GAAUSP2MAPT | |
| SCHEMBL21045899 | 0.76 | MEN1 (0.61) | KMT2AMEN1GAAMAPTHTT | |
| SCHEMBL21045897 | 0.76 | MEN1 (0.61) | KMT2AMEN1GAAMAPTHTT | |
| SCHEMBL21045896 | 0.76 | MEN1 (0.61) | KMT2AMEN1GAAMAPTHTT | |
| SCHEMBL21045982 | 0.73 | MEN1 (0.57) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL21045983 | 0.73 | MEN1 (0.57) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL24121635 | 0.72 | MEN1 (0.57) | KMT2AMEN1MAPTNPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11191754-B2 | Inhibitors of nucleotidyl transferases and uses in herpes and hepatitis viral infections therefor | SAINT LOUIS UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20180169083-A1 | INHIBITORS OF NUCLEOTIDYL TRANSFERASES AND USE IN HERPES AND HEPATITIS VIRAL INFECTIONS THEREFOR | SAINT LOUIS UNIVERSITY (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180169083-A1 | INHIBITORS OF NUCLEOTIDYL TRANSFERASES AND USE IN HERPES AND HEPATITIS VIRAL INFECTIONS THEREFOR | SAINT LOUIS UNIVERSITY (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2016201306-A2 | INHIBITORS OF NUCLEOTIDYL TRANSFERASES AND USE IN HERPES AND HEPATITIS VIRAL INFECTIONS THEREFOR | SAINT LOUIS UNIVERSITY (US) | 2016-12-15 | — | — | WO | disclosed |
| EP-2762150-A1 | Treatment of Diabetes and Metabolic Syndrome | Nordic Bioscience A/S (DK) | 2014-08-06 | — | — | EP | disclosed |
| EP-2405934-B1 | Treatment of diabetes and metabolic syndrome | NORDIC BIOSCIENCE AS (DK) | 2014-03-26 | — | — | EP | disclosed |
| US-20120046224-A1 | TREATMENT OF DIABETES AND METABOLIC SYNDROME | NORDIC BIOSCIENCE A/S (DK) | 2012-02-23 | — | — | US | disclosed |
| US-20120046224-A1 | TREATMENT OF DIABETES AND METABOLIC SYNDROME | NORDIC BIOSCIENCE A/S (DK) | 2012-02-23 | — | — | US | disclosed |
| WO-2010103045-A1 | TREATMENT OF DIABETES AND METABOLIC SYNDROME | NORDIC BIOSCIENCE A/S (DK) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191754-B2 | Inhibitors of nucleotidyl transferases and uses in herpes and hepatitis viral infections therefor | TYMP, PNP, ENTPD5 | KMT2A 2508/4885MEN1 3939/4885GAA 121/4885 |
| US-20180169083-A1 | INHIBITORS OF NUCLEOTIDYL TRANSFERASES AND USE IN HERPES AND HEPATITIS VIRAL INFECTIONS THEREFOR | TYMP, PNP, NTPCR | KMT2A 2478/4885MEN1 3920/4885GAA 127/4885 |
| US-20120046224-A1 | TREATMENT OF DIABETES AND METABOLIC SYNDROME | IAPP, GLP1R, CALCA | KMT2A 4693/4885MEN1 83/4885GAA 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.